Will Seaport Therapeutics announce a new clinical trial phase for one of its drug candidates by December 31, 2028?

As a drugmaker, Seaport's long-term success hinges on its pipeline development. An upsized IPO provides capital for accelerating R&D. This question gauges the company's progress in advancing its drug candidates.

Implied probability (Yes)

45%

Closes

2030-07-30